NDC 0008-0100-01
Besponsa .25 mg/mL
inotuzumab ozogamicin · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Besponsa is a injection, powder, lyophilized, for solution containing inotuzumab ozogamicin at a strength of .25 mg/mL. Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
Key Facts
- Brand Name
- Besponsa
- Generic Name
- inotuzumab ozogamicin
- NDC Code (Package)
0008-0100-01- NDC Code (Product)
0008-0100- Manufacturer
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- Strength
- .25 mg/mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761040
- Drug Class
- CD22-directed Immunoconjugate [EPC]
- Marketing Start
- 08/18/2017
Recall History
No Recall HistoryView Full Drug Page
Besponsa — All PackagesNot medical advice. This information is for reference only. Always consult your doctor or pharmacist.